Revelation Biosciences Stock Price, News & Analysis

Revelation Biosciences (NASDAQ: REVB) has announced a $4 million public offering, pricing 3,640,000 shares of common stock at $1.10 per share. The offering includes warrants to purchase up to 14,560,000 additional shares, also at $1.10 per share, exercisable for 5 years after stockholder approval. Roth Capital Partners is serving as the sole placement agent. The proceeds will fund: (1) completion of ongoing Phase 1b clinical study, (2) clinical drug supply manufacturing, (3) preclinical work for multiple indications, (4) development of other products/therapies, and (5) working capital. The offering is expected to close around May 29, 2025, subject to customary conditions.

Revelation Biosciences (NASDAQ: REVB) announced the retirement of George F. Tidmarsh, MD, PhD from its Board of Directors. Dr. Tidmarsh, who served on the board for 5 years, is stepping down to avoid potential conflicts of interest as he takes on new responsibilities working with US governmental agencies in his role as Adjunct Professor of Pediatrics and Neonatology at Stanford University School of Medicine. CEO James Rolke expressed gratitude for Dr. Tidmarsh's guidance and support during his tenure.

Revelation Biosciences (NASDAQ: REVB) reported its Q1 2025 financial results and corporate updates. The company highlighted progress with its Gemini program, including a new indication for severe burn patients and data showing inflammation attenuation in peripheral blood mononuclear cells. Revelation also completed first patient dosing in the PRIME Phase 1b Clinical Study of Gemini in CKD patients, with topline data expected in summer 2025. Financially, REVB reported cash and cash equivalents of $3.7 million as of March 31, 2025, down from $6.5 million at year-end 2024. The company's Q1 2025 net loss was $2.1 million ($(2.11) per share), compared to $2.7 million ($(39.37) per share) in Q1 2024. Current cash runway extends through June 2025, with quarterly cash burn of $2.8 million remaining stable year-over-year.

Revelation Biosciences (NASDAQ: REVB) has announced plans to develop its Gemini Platform for preventing infections in severe burn patients requiring hospitalization (GEM-PBI program). This initiative builds upon their existing work on preventing post-surgical infections (GEM-PSI program).

The company is collaborating with Vanderbilt University, from whom they previously licensed the patent family. Dr. Julia Bohannon, Associate Professor at Vanderbilt, reported that Gemini's clinical biomarker activity aligns with their preclinical infection burn models. Research shows the treatment reduces pseudomonas lung infection severity and duration while lowering overall inflammation levels.

CEO James Rolke emphasized that this expansion into burn patient care complements Revelation's existing work, noting that the Gemini-PBI program may present new opportunities in regulatory approval, development, and funding.

Revelation Biosciences (NASDAQ: REVB) announced positive results from a study showing that Gemini effectively reduces inflammation in human peripheral blood mononuclear cells (PBMCs). The study demonstrated that Gemini-primed PBMCs, when exposed to inflammatory promoters HMGB-1 and LPS, showed significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines compared to placebo.

The company is currently conducting a Phase 1b PRIME clinical study in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), with top-line data expected by mid 2025. This data will include safety, tolerability, and cellular-level protection assessment, supporting future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.

Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced its participation in the 37th Annual Roth Conference. James Rolke, the company's Chief Executive Officer, will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.

The event will be accessible through a live webcast and will subsequently be available for viewing in the Investors section of Revelation's website at www.RevBiosciences.com. Interested investors can arrange meetings with the management team through their Roth representatives.

Revelation Biosciences (NASDAQ: REVB) has reported its financial results for Q4 and full-year 2024. The company ended the year with $6.5 million in cash, down from $12.0 million in 2023. Key developments include the initiation of the PRIME Phase 1b Clinical Study of Gemini in CKD Patients, FDA acceptance of Gemini IND, and securing $3.7 million from warrant exercises in December 2024.

Financial performance shows a net loss of $1.7 million ($4.98 per share) for Q4 2024, compared to $2.2 million loss in Q4 2023. The full-year 2024 resulted in a net loss of $15.0 million ($87.68 per share) versus $0.1 million loss in 2023. Cash used in operations increased to $18.3 million in 2024 from $7.3 million in 2023. Management believes current cash positions are sufficient to fund operations into 2025.

Revelation Biosciences (NASDAQ: REVB) has initiated patient dosing in its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of Gemini. The study focuses on evaluating intravenous single ascending doses in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).

The US-based, multi-site, placebo-controlled trial will include up to forty patients across five cohorts. The company expects to release top-line data by mid-year, which will assess safety, tolerability, and key biomarkers of activity, including attenuation of the inflammatory response. Results from this PRIME study will support future development of both GEM-CKD and GEM-AKI programs.

Revelation Biosciences (NASDAQ: REVB) has received formal notification from Nasdaq confirming its continued listing status, having met all compliance requirements. The company recently initiated its PRIME Phase 1b clinical study investigating intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).

The U.S. multi-site placebo-controlled study will evaluate escalating doses across five cohorts, enrolling up to 40 patients. CEO James Rolke emphasized that maintaining Nasdaq listing helps preserve stockholder liquidity, provides capital access, and aids in talent retention. The company plans to share study results with shareholders at each milestone throughout 2025.